The biotechnology company Celgene agreed Tuesday to pay $7.2 billion in cash to acquire Receptos, which is developing a potentially promising drug for autoimmune diseases.
Celgene will pay $232 a share, a 12 percent premium to Receptos’s closing price on Tuesday. The deal was announced after markets had closed.
10:57 CMO Today: AT&T’s Ambitious Advertising Plans With Time Warner Deal28
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner11
11:10 Merged BAT-Reynolds could be loaded with up to $55 billion of debt, analysts say7
23:06 AT&T discussed takeover in meetings with Time Warner: Bloomberg3